Strides Pharma debuts with a stellar ESG rating of 76/100 in the S&P Global’s CSA 2024
With this achievement, Strides has secured a position in the 94th percentile among its peers in the DRG Global Pharmaceuticals industry
With this achievement, Strides has secured a position in the 94th percentile among its peers in the DRG Global Pharmaceuticals industry